compounding glp-1 Compounded Treatment Is the GLP-1 compounding boom

Clinicians and patients should be aware that access to these medicines outside of clinical trials is not currently possible through NHS pathways

With the effects seen of the GLP-1 family of drugs on preventing kidney damage in diabetes, liver disease (non-alcoholic or metabolic-associated steatosis, NASH/MASH), and addiction, this drug class is exceeding all expectations

In some embodiments, the otic formulation or composition comprises between about 0.01% to about 70% by weight of the therapeutic agent, or pharmaceutically acceptable prodrug or salt thereof

Accessed June 4, 2026 at Further information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Sperm count is a growing concern for many of the couples we hear from, too